David Wofsy, MD

Professor

Dr. Wofsy received his undergraduate degree from Harvard (1968), his MD from the University of California, San Diego (1974), and his medical residency training and rheumatology fellowship training from the University of California, San Francisco. He joined the UCSF faculty in 1980. He currently Professor of Medicine and Microbiology/Immunology at UCSF. Dr. Wofsy also serves as Associate Dean for Admissions for the UCSF School of Medicine. He has served on numerous NIH study sections, and on the Arthritis Advisory Committee of the Food and Drug Administration. Dr. Wofsy is a past-President of the American College of Rheumatology.

Dr. Wofsy's research program is devoted to the development of novel therapies for autoimmune diseases, particularly systemic lupus erythematosus (SLE). For many years, his research focused on the cellular and molecular mechanisms that lead to autoimmunity in murine models for SLE. These therapies are designed to block pathologic immune responses without damaging the entire immune system. One of the therapies that was pioneered by Dr. Wofsy's group involves the B7 family of molecules on antigen-presenting cells (APC). These molecules play a pivotal role in the generation of T-cell help. Specifically, the interaction of B7 molecules on APC with their ligand (designated CD28) on T cells provides an important signal for T-cell activation. Dr. Wofsy first showed that selective inhibition of the B7-CD28 interaction retards autoimmunity in murine lupus. He subsequently showed that this beneficial effect could be enhanced substantially in two ways: (i) by combining blockade of B7-CD28 with blockade of other receptor-ligand pairs (CD40-CD40L) on the surface of T cells and APC; and (ii) by combining blockade of B7-CD28 with cyclophosphamide therapy. In each case, combination therapy provided a prolonged benefit without sustained generalized immune suppression. This work laid the foundation for translational studies that resulted in FDA approval of a new treatment for rheumatoid arthritis. Dr.Wofsy's current research is focused on establishing whether this therapy can be life-saving in people with kidney disease due to SLE.
Education
2017 - Diversity, Equity, and Inclusion Champion Training, University of California
Residency, - School of Medicine, University of California, San Francisco
Honors and Awards
  • Master of the American College of Rheumatology, American College of Rheumatology, 2012
  • Paul Klemperer Award and Medal, New York Academy of Medicine, 2011
  • Lee C. Howley Sr. Prize, Arthritis Foundation, 2007
  • Arthritis Hero Award, Arthritis Foundation, 2001
  • Edmund L. Dubois Award for Outstanding Research in SLE, American College of Rheumatology, 1999
Websites
Publications
  1. Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH, Accelerating Medicines Partnership RA/SLE network , Petri MA, Buyon JP. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. 2021. PMID: 34389634


  2. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Lim SS, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. 2020. PMID: 32755035


  3. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. 2020. PMID: 32816709


  4. Wofsy D. A Tale of Two Trials. 2020. PMID: 32182394


  5. Fava A, Buyon JP, Mohan C, Zhang T, Belmont HM, Izmirly P, Clancy R, Monroy Trujillo J, Fine DM, Zhang Y, Magder L, Rao DA, Arazi A, Berthier CC, Davidson A, Diamond B, Hacohen N, Wofsy D, Apruzzese W, Accelerating Medicines Partnership T, Raychaudhuri S, Petri M. Integrated urine proteomics and renal single-cell genomics identify an interferon-? response gradient in lupus nephritis. 2020. PMID: 32396533


  6. Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K. The Validity of Scores from the New MCAT Exam in Predicting Student Performance: Results from a Multisite Study. 2019. PMID: 31425189


  7. Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A. The Accelerating Medicines Partnership - Organizational Structure and Preliminary Data from the Phase 1 Studies of Lupus Nephritis. 2019. PMID: 31502417


  8. Craft JE, Crow MK, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin JA, Koopman WJ, Lockshin MD, Salmon JE, Seaman WE, Sergent JS, Uknis AB, Weinblatt ME, Wofsy D. Georgia Abortion Law and our Commitment to Patients. 2019. PMID: 31637878


  9. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise E, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA. PD-1hi CXCR5- T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. 2019. PMID: 31536480


  10. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. 2019. PMID: 31409923


  11. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. 2019. PMID: 31385462


  12. Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P. Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. 2019. PMID: 31528843


  13. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. 2019. PMID: 31383717


  14. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. The immune cell landscape in kidneys of patients with lupus nephritis. 2019. PMID: 31209404


  15. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P. Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools. 2018. PMID: 30188370


  16. Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. 2019. PMID: 30692164


  17. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD. Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus. 2018. PMID: 30277008


  18. Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M. Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. 2018. PMID: 30554156


  19. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools? 2018. PMID: 29561273


  20. Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P. Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. 2017. PMID: 29095170


  21. Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L. Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. 2018. PMID: 30197972


  22. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Volume 70 of Issue 4. 2018. PMID: 28692774


  23. Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools. Volume 17 of Issue 1. 2017. PMID: 29110662


  24. Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Volume 4 of Issue 1. 2017. PMID: 29214037


  25. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Volume 69 of Issue 1. 2016. PMID: 27390168


  26. Wofsy D. In memoriam: Ephraim P. Engleman, MD, 1911-2015. Volume 67 of Issue 11. 2015. PMID: 26508466


  27. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Volume 2 of Issue 1. 2015. PMID: 26023331


  28. Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Volume 67 of Issue 5. 2015. PMID: 25779381


  29. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Volume 65 of Issue 6. 2013. PMID: 23529285


  30. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Volume 64 of Issue 11. 2012. PMID: 22806274


  31. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. Volume 365 of Issue 20. 2011. PMID: 22087680


  32. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. Volume 38 of Issue 5. 2011. PMID: 21285160


  33. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Volume 63 of Issue 3. 2010. PMID: 21080348


  34. Papadakis MA, Wofsy D. Plagiarism on personal statements: a disturbing symptom of a broader trend. Volume 153 of Issue 2. 2010. PMID: 20643994


  35. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Volume 6 of Issue 3. 2010. PMID: 20197774


  36. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Volume 9 of Issue 44. 2010. PMID: 20102681


  37. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Volume 49 of Issue 1. 2009. PMID: 19933596


  38. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Volume 5 of Issue 10. 2009. PMID: 19798031


  39. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Volume 5 of Issue 6. 2009. PMID: 19491915


  40. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Volume 20 of Issue 5. 2009. PMID: 19369404


  41. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. Volume 301 of Issue 13. 2009. PMID: 19336712


  42. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E. A quality indicator set for systemic lupus erythematosus. Volume 61 of Issue 3. 2009. PMID: 19248127


  43. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Volume 56 of Issue 12. 2007. PMID: 18050206


  44. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Volume 16 of Issue 12. 2007. PMID: 18042591


  45. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Volume 18 of Issue 5. 2006. PMID: 16896285


  46. Daikh DI, Gillis J, Wofsy D. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Volume 55 of Issue 2. 2006. PMID: 16583382


  47. Wofsy D. Living in a different world. Volume 52 of Issue 2. 2005. PMID: 15692996


  48. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Volume 14 of Issue 3. 2005. PMID: 15807196


  49. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Volume 46 of Issue 12. 2002. PMID: 12483729


  50. Wofsy D, Daikh DI. Treatment of autoimmune diseases by inhibition of T-cell costimulation. Volume 12 of Issue 1. 2002. PMID: 24383824


  51. Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Volume 44 of Issue 8. 2001. PMID: 11508422


  52. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. Volume 166 of Issue 5. 2001. PMID: 11207238


  53. Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V. Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets. 2001. PMID: 11168938


  54. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. Volume 28 of Issue 1. 2001. PMID: 11196549


  55. Daikh DI, Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Volume 490. 2001. PMID: 11505969


  56. Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ. The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. 1999. PMID: 10583610


  57. Daikh DI, Wofsy D. Effects of anti-B7 monoclonal antibodies on humoral immune responses. Volume 12 of Issue 2. 1999. PMID: 10047430


  58. Daikh DI, Wofsy D. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Volume 30 of Issue 8. 1998. PMID: 9865285


  59. Wofsy D, Daikh DI. Opportunities for future biological therapy in SLE. Volume 12 of Issue 3. 1998. PMID: 9890111


  60. Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Volume 87 of Issue 1. 1998. PMID: 9576007


  61. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Volume 159 of Issue 7. 1997. PMID: 9317105


  62. Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. Volume 62 of Issue 2. 1997. PMID: 9261329


  63. Adleman LM, Wofsy D. Blind T-cell homeostasis in CD4-deficient mice. 1996. PMID: 8601219


  64. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Volume 265 of Issue 5176. 1994. PMID: 7520604


  65. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. Volume 94 of Issue 2. 1994. PMID: 8040314


  66. Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection . 1993. PMID: 8094457


  67. Finck BK, Yung CM, Carteron NL, Wofsy D. The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies. 1992. PMID: 1360341


  68. Jäck HM, Beck-Engeser G, Lee G, Wofsy D, Wabl M. Tumorigenesis mediated by an antigen receptor. 1992. PMID: 1528851


  69. Wofsy D, Carteron NL. CD4 antibody therapy in systemic lupus erythematosus. Volume 2 of Issue 6. 1990. PMID: 2104279


  70. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. Volume 144 of Issue 5. 1990. PMID: 2307839


  71. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Volume 52 of Issue 3. 1989. PMID: 2758698


  72. Erlich KS, Wofsy D, Dix RD, Mills J. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Volume 52 of Issue 2. 1989. PMID: 2525439


  73. Klippel JH, Strober S, Wofsy D. New therapies for the rheumatic diseases. 1989. PMID: 2670022


  74. Wofsy D. The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. Volume 1 of Issue 2. 1988. PMID: 2978113


  75. Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. 1986. PMID: 2947360


  76. Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. 1986. PMID: 3090139


  77. Stanton T, Stevens TL, Ledbetter JA, Wofsy D. Anti-Ly-1 antibody induces interleukin 2 release from T cells. 1986. PMID: 3081630


  78. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. 1985. PMID: 3928743


  79. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. Treatment of murine lupus with monoclonal anti-T cell antibody. Volume 134 of Issue 2. 1985. PMID: 3871218


  80. Wofsy D. [Not Available]. Volume 5 of Issue 7. 1984. PMID: 25289950


  81. Wofsy D. Hormones, handedness, and autoimmunity. Volume 5 of Issue 6. 1984. PMID: 25289744


  82. Wofsy D, Kerger CE, Seaman WE. Monocytosis in the BXSB model for systemic lupus erythematosus. 1984. PMID: 6363600


  83. Talal N, Dauphinee MJ, Wofsy D. Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Volume 25 of Issue 7. 1982. PMID: 6285934


  84. Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N. Thymic influences on autoimmunity in MRL-lpr mice. 1982. PMID: 6981841


  85. Dauphinée MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. 1981. PMID: 6975325


  86. Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. 1981. PMID: 6975351


  87. Wofsy D, Dauphinée MJ, Kipper SB, Talal N. Interleukin-2 deficiency in murine systemic lupus erythematosus. 1981. PMID: 6979821


  88. Loeb JM, Livermore BM, Wofsy D. Coccidioidomycosis of the thyroid. 1979. PMID: 475170